ABSTRACT
In this article “new cost-effective RP-HPLC method development and validation for quantitative estimation of ivacaftor in the pharmaceutical formulation” developed. This study includes RP-HPLC Spectrophotometric method development, such as economical and simple HPLC method was optimized during development and validated accordingly in tablets of ivacaftor. The developed method may utilize for the analysis of ivacaftor at the laboratory level. The result shows that developed methods are cost-effective, rapid (Short retention time), simple, accurate (the value and %RSD between 2-5), precise, and can be used for the intended purpose on the tablet dosage form. The present proposed method is capable of better separation of analyte and qualifies on the point of analytical validation such as linearity, specificity, accuracy, precision, robustness, LOD, and LOQ on a marketed formulation. The simplicity, rapidity, and reproducibility of the developed method qualify the objective of the research. Results of analysis of the ivacaftor tablet formulations are arranged in the experimental result, and discussion section. The portion of ivacaftor found in terms of quantity was between 98-102% and also within USP 29 chapter (S41) acceptance criteria.

Keywords: Cystic fibrosis, validation, adsorption chromatography, ich guidelines, spectroscopic system.

INTRODUCTION
Validation of method is the process that is used to guarantee that the strategy of analytical parameters applied for a specific test is appropriate for its quality intended purpose. Summary of experimental results from method validation used to confirm the reliability, quality, reproducibility of analytical aspects. 1-3 These are the parameters valid for developing new methods of analysis:

This method may not be suitable for certain analysis analyzes for a special sample pool. When any existing method too expensive, time-consuming, or energy-consuming or May not easily adaptable during automation5-5 The current intended method may not be adequate for selectivity and sensitivity to provide acceptable parameters in all conditions. Current methods may compose a lot of errors, non-artifact, and/or adulterated methods, or they may be irreproducible (serve poor accuracy or precision). 5-7 Latest techniques with new instrumentation may provide an opportunity to improve the existing method as a new one. May improve analyte identification or detection capacity, perfect accuracy or precision or better output on investment. 8-11

The solute present in the mobile phase passes through the column or plate in the chromatography technique. The passage of solute or test sample is called chromatographic development.12 Chromatographic development is mainly tree types

1. Elution development
2. Displacement development
3. Frontal analysis

Elution development is mainly used in gas chromatography and liquid chromatography but sometimes displacement technique is used in preparative liquid chromatography. In thin-layer chromatography, multi-sample solvent development is based on the frontal analysis but it is sometimes confused that’s based on the mobile phase passage.13-14

Figure 1: The development process in chromatography
The quantitative estimation of the active constituents is an integral part of the developing and manufacturing process of pharmaceutical dosage forms. Slight changes in the composition or in the purity of the drug itself can affect the therapeutic value. \(15\)-\(16\) Therefore, there is a need for the development of better and reliable methods for the estimation of the pharmaceutical dosage form. New methods however have to be devised and developed for the estimation of the drugs. \(17\)-\(18\)

The official methods for the analysis of active ingredients of formulations are few and most of the methods available for the analysis of active ingredients are applicable only after prior separation that involves tedious and time-consuming procedures \(19\)-\(20\)

Therefore, in the present study, an attempt is made to develop the RP-HPLC method for the analysis and method development of the drug in pure and pharmaceutical formulations. \(21\) This research study aims to develop and validate simple, accurate, precise, sensitive, and cost-effective RP-HPLC method for quantitative evaluation of Ivacaftor in pharmaceutical formulations,

Which is critical for the quality control laboratories?

Ivacaftor synthetic is a quinoline and used to treat cystic fibrosis, it was approved by the Food and Drug Administration on January 31, 2012. Each tablet/granule of Ivacaftor contains the commonly prescribed daily doses of 150 mg. \(23\)-\(23\)

**MATERIALS AND METHODS**

The present work has been done on Agilent HPLC. It has 6029 series pumps, an auto sampler with a 100-microlitre loop, U.V. Vis. Detector, Inertsil ODS 3V-250mm, 5\(\mu\) particle size) with Chromalion 6.8 version software. Chemicals/Reagents used were Acetonitrile, Methanol, Ortho-phosphoric acid Water. \(24\)

**Diluent**

Prepared a mixture of acetonitrile and methanol in the ratio of \((60:40)\) v/v sonicated for 10 minutes.

**Mobile Phase**

Prepared a mixture of acetonitrile and methanol in the ratio of \((60:40)\) v/v sonicated for 10 minutes, allowed to attain room temperature. \(25\)

**Preparation of standard stock solution**

Transfer an accurately weighed 25mg of Ivacaftor standard into a 50 ml volumetric flask, added 30ml of diluent, and sonicated to dissolve. Make volume up to the mark with diluent and mixed well. Diluted 5ml of above standard stock to 50ml with diluent and mixed well, \(26\)-\(27\)

**Preparation of sample Stock Solution:**

Marketed formulation 20 tablets of Ivacaftor were taken and calculate average weight than made a fine powder with the help of mortar pestle. \(28\) The powder equivalent to 100 mg = of Ivacaftor was taken and into 100 ml volumetric flask added 65 ml of acetonitrile sonicated for 30 minutes with intermittent shaking, allowed to attain room temperature make volume up to the mark with methanol and mixed. Centrifuge solution at 3500 rpm for 10 minutes. The resulting concentration of test sample 1mg/ml (1000 PPM) of Ivacaftor was used in further study and validation. \(29\)-\(30\)

**RESULT AND DISCUSSION**

**Physical Characterization**

In this study physical properties on the observation basis were recorded by spreading Ivacaftor powder in Petri plate.

1. Physical Nature - Crystalline powder  
2. Colour - off white  
3. Odour - Odourless  
4. Taste - Pungent

**Solubility Study**

Weighed accurately 1 gram of Ivacaftor powder 6 times and transferred in Six different 100 ml volumetric flasks, then add solvent in required quantity respectively. Sonicated and observed solubility and precipitation within the account on mind clearness of solvent system with Ivacaftor powder. See below for solubility behavior.

**Table 1: Solubility behavior of ivacaftor**

| S.no. | Solvent            | Physical Behavior  |
|-------|--------------------|---------------------|
| 1     | Dimethyl sulfoxide | Soluble             |
| 2     | Methanol           | Freely Soluble      |
| 3     | Water              | Sparingly Soluble   |
| 4     | Ethanol            | Soluble             |
| 5     | pH 6.8 Phosphate Buffer | Soluble          |
| 6     | Acetonitrile       | Freely Soluble      |

**Melting Point**

Taken capillary and filled with Ivacaftor capillary with thermometer then dip it into the tube which previously contains liquid paraffin, heat gently with burner and record the degree of melting of Ivacaftor. The melting point of the Ivacaftor record from 291°C to 295°C and the final melting point of the Ivacaftor is 293°C.

**Infrared Spectral Analysis**

Taken 2 mg of Ivacaftor with 400 mg of potassium bromide in mortar pestle then mixed well and made a uniform fine mixture.

![Figure 2: IR Spectra of Ivacaftor](image)
The Ivacaftor solution was scanned on a UV spectrophotometer at 200-400nm to determine $\lambda_{\text{max}}$. Maximum absorbance showed on 225 nm.

Figure 3: Determination of $\lambda_{\text{max}}$ of Ivacaftor

An analytical method, a series of dilutions ranging from 5-25µg/ml was prepared in the diluent. Absorbance was recorded at 225nm. A calibration graph was plotted between absorbance and respective concentration and the regression equation was derived.

Table 2: Linearity of ivacaftor

| Concentration (µg/ml) | Absorbance | Statistical Analysis |
|----------------------|------------|----------------------|
| 5                    | 0.1547     | Slope = 0.0337       |
| 10                   | 0.3192     | Intercept = 0.0188   |
| 15                   | 0.4803     | Correlation coefficient = 0.999 |
| 20                   | 0.6454     |                      |
| 25                   | 0.8341     |                      |

Validation of Developed Method

Linearity

After analysis of five different (from 5 to 25 µg/ ml) concentrations and areas for each concentration were recorded.

Table 3: Response ratio data for linearity of ivacaftor

| Concentration (µg/ml) | Area Response | Response Ratio |
|----------------------|---------------|----------------|
| 5                    | 410.258       | 82.05          |
| 10                   | 826.145       | 82.61          |
| 15                   | 1268.214      | 84.55          |
| 20                   | 1654.978      | 82.75          |
| 25                   | 2101.478      | 84.06          |

Response ratio Mean 83.20
SD 1.05
RSD % 1.26

Figure 5: Response ratio curve of ivacaftor

Specificity

Chromatogram of Ivacaftor at 5.81 Minutes retention time

Figure 6: Chromatogram of ivacaftor

Accuracy & Recovery

Applying the analytical procedure of the standard sample from the range of 80%, 100%, and 120% level of the test concentration.
Recovery is calculated as
Area of test × dilution of std. × potency
Conc. obtained = \frac{\text{Area of test} \times \text{dilution of std.} \times \text{potency}}{\text{Area of std.} \times \text{dilution of test}}

Table 4: Recovery studies of ivacaftor formulation

| Initial Amount of stock (mg) [A] | Addition of known quantity (ml) [B] | Final Conc. (µg/ml) | % Recovery | Average Recovery n=3 |
|----------------------------------|-------------------------------------|--------------------|------------|---------------------|
| 100                              | 2                                   | 80                 | 98.82      | 99.5                |
|                                  |                                     |                    | 97.97      |                     |
|                                  |                                     |                    | 101.85     |                     |
| 100                              | 2.5                                 | 100                | 99.54      | 99.9                |
|                                  |                                     |                    | 101.97     |                     |
|                                  |                                     |                    | 98.07      |                     |
| 100                              | 3.0                                 | 120                | 101.17     | 99.7                |
|                                  |                                     |                    | 98.71      |                     |
|                                  |                                     |                    | 99.22      |                     |

Precision

The precision is established in three differences:
1. Repeatability
2. Intermediate precision
   a) Day to day
   b) Analyst to analyst

Table 5: Repeatability of Ivacaftor

| Injection No. | Concentration | Area Response | Tailing Factor | Theoretical Plate |
|---------------|---------------|---------------|----------------|-------------------|
| 1             | 100 µg/ml     | 3256.12       | 1.0            | 7453              |
| 2             | 100 µg/ml     | 3289.45       | 1.0            | 7654              |
| 3             | 100 µg/ml     | 3296.91       | 1.1            | 7458              |
| 4             | 100 µg/ml     | 3241.89       | 1.0            | 7412              |
| 5             | 100 µg/ml     | 3263.49       | 1.1            | 7463              |
| 6             | 100 µg/ml     | 3301.24       | 1.1            | 7501              |
| Average SD % RSD | 3274.9       | 1.1           | 7490.2         |
|                | 24.3          | 0.1           | 85.1           |
|                | 0.7           | 5.2           | 1.1            |

Intermediate Precision

Day to day precision

Table 6: Result of day-to-day intermediate precision of ivacaftor

| Concentration | Area Response | Tailing Factor | Theoretical Plate |
|---------------|---------------|----------------|-------------------|
| 5 µg/ml       | 412.146       | 1.0            | 7453              |
| 10 µg/ml      | 830.731       | 1.0            | 7654              |
| 15 µg/ml      | 1258.961      | 1.1            | 7458              |
| 20 µg/ml      | 1664.328      | 1.0            | 7412              |
| 25 µg/ml      | 2098.257      | 1.1            | 7463              |
| Value of R²   | 0.999         |                |                   |

Robustness

A working solution of 100 µg/ml (100 PPM) for Ivacaftor was taken and the following method parameters were changed independently of each other.

- Mobile phase ratio (±2%)
- Flow rate (±0.2 ml/min)

Injected three times each with changes in parameters.

Acceptance Criteria: % RSD Not more than 5.0%
**Table 7: Robustness of Ivacaftor**

| Flow rate(ml/min) | Variation | Retention Time |
|-------------------|-----------|----------------|
| 0.8               | -0.2      | 6.05 Minutes   |
| 1                 |           | 5.82 Minutes   |
| 1.2               | +0.2      | 5.57 Minutes   |

RSD% 4.13

| % of Acetonitrile | % of Methanol | Variation | Retention Time |
|-------------------|---------------|-----------|----------------|
| 45                | 25            | -5 ml     | 6.12 Minutes   |
| 50                | 30            | 0         | 5.89 Minutes   |
| 55                | 35            | +5 ml     | 5.68 Minutes   |

RSD% 3.7

**limit of Detection (LOD)**

The LOD was calculated as 0.1412 µg/ml of Ivacaftor

**Limit of Quantification (LOQ)**

The LOQ was calculated as 0.5478 µg/ml of Ivacaftor.

**CONCLUSION**

The result shows that developed methods to be Cost-effective, Rapid (Short retention time), Simple, Accurate (the value and %RSD between 2-5), Precise, and can be used for intended purposes on the tablet dosage form. The Simplicity, Rapidly and Reproducibility of the developed method qualify the objective of the research. Results of analysis of the Ivacaftor tablet formulations are arranged in the experimental, result, and discussion section. The portion of Ivacaftor found in terms of quantity was between 98-102% and also within USP acceptance criteria.

This "New Cost-Effective RP-HPLC Method Development and Validation for Quantitative Estimation of Ivacaftor in Pharmaceutical Formulation" includes RP-HPLC, Spectrophotometric method. The economical and simple HPLC method was optimized during development and validated accordingly in tablets of Ivacaftor. The developed method may utilize for the analysis of Ivacaftor at the laboratory level.

**REFERENCES**

1. Ravishankar P, Devadasu C, Shrinivasa D, Rao GD, Gananathamu and Sowjanya S. New spectrophotometric techniques for the quantitative investigation of Ivacaftor in the pharmaceutical dosage form. Int. J. Chem. Sci. 2010; 8(4): 2309-24.

2. Gurdeep R. Chatwal, Sham K. Anand, “Instrumental Method of Chemical Analysis,” 5th Edition, 2009; PP- 570 and 624, 566-567.

3. A.H. Beckett, J.B. Stenlake, “Practical Pharmaceutical Chemistry,” Part –II, 5th Edition, 2015; PP- 279-282 and 287, 273.

4. Sweetman SC. Martindale: The Complete Drug Reference. Pharmaceutical Press, London, 2002; 1: 2188-2197.

5. Arai Y, Ohara H, Ichioka K, Koji Y, Terai A, International Journal of Urology, 2004; 11 (10): 870.

6. K N Vishwottam, N V S Ramakrishna, S Manoj, M Koteshwara, S Wishu, D P Varma, Biomedical Chromatography, 2014; 19: 709 – 719.

7. Journal of Chromatography Biomedical Sciences and Application, Issue Nov.2009; (1): PP- 195-199.

8. Goodman SL, Gilman A, General principle. A textbook of pharmacology, toxicology for medicinal students and physicians. New York, MacMillan Company,2000; 2-46.

9. Sethi PD, HPLC quantitative analysis of pharmaceuticals. New Delhi, CBS Publishers & Distributors, 2000; 1-211.

10. Sethi PD, Identification of the drug in pharmaceutical formulations by TLC New Delhi, CDS distributor, 1999; 1-52.

11. Sidney HW, James RS, Good manufacturing practices for pharmaceuticals 5th Edition. U.S.A., 2001; 10-16.

12. Hokanson GC, The initial validation process. A life cycle approach to the validation of analysis method during pharmaceutical product development, Pharm Tech Pub,1994; (1): 118–130.

13. Caruso S, Di ML, Cacciatore A, Mamana G, Agnello C, Cianci A, Prophylaxis with Ivacaftor antibiotic cystic fibrosis. Minerva Ginecol. 2008; 60(1): 1-5.

14. Huang Y, Tang Y, Liu B, Gao X, Yan J, Zi Y, Yu Z, Spectroct him Acta A Mol Bio mol Spectrosc, 2010; 75(3): 1024-9.

15. Addonisio P, Cai T, Mazzoli S, Pagliari RC, Bechi AN, Bartoletti R, Mondaini N, Int J Anti-microb Agents, 2009; 33(6): 549-53.

16. Tang YC, Zi YQ, Huang YB, Wang SJ, Yu Z, Gao XY, Zheng DM, Chem Pharm Bull, 2010; 58(4): 582-6.

17. Yu F, Chen F, Liu W, Cai P, Highly delicate spectrofluorimetric assurance of trace amount of Ivacaftor using the aluminum (III) Ivacaftor system. Luminescence, 2008; 23(6): 429-33.

18. Guo L, Qi M, Jin X, Wang P, Zhao H, Determination of active metabolite of Ivacaftor in human plasma by fluid chromatography-mass spectroscopy. J Chromatogr B AnalytTechnol Biomed Life Sci, 2006; 832(2): 280-5.

19. Zhang L, Li Z, Wen J, Wu Y, Pan Y, Fan G, Biomed Journal of life sciences, 2008; 872(1-2): 172-6.

20. Philip K, Shindler M, Yatoma A, Ciottoli GB, In vitro and In vivo experiments of cardiac-related disease. Eur J Pharmocol, 2003; 477(1): 69-72.

21. D. R. Chaple, A. G. Sambhar. Validated stability indicating HPLC method for Ivacaftor. International Journal of Pharmacy and Technology, 2010; 1(2): 137-148.

22. Schreiber MS, "Chromatography-an Historical Dialogue", 8thNew York, Elsevier Scientific Publishing Company 1975; 413.

23. Pokharkar D, JadhavV. GholveS. Kadam V. estimation of Ivacaftor in tablet dosage form. Int. Journal of Pharm tech research. 2010; 2(1): 960-963.

24. Brown RP, Gruskha E. Advance in chromatography. Marcel Dekker Inc. 2003: 42; 95.
25. Valcarcell M, CastroLuque MD. Automatic methods of analysis, Elsevier publisher B.V, 1988: 9; 369-377.

26. Shankar RS. High-Performance Liquid Chromatography, Textbook of pharmaceutical analysis, 1st edition. Madras, Neelma Printers, 1997; 18-1 to 18-15.

27. Mansoor AK, Indra KR. Pharmaceutical and clinical calculations. Florida, CRC Press LLC, 2000.

28. Gennaro AR. Remingtons the science and practice of pharmacy 19th edition. Mack Publishing Company; 1995.

29. David NM. High-performance LC in chromatography in pharmaceutical bio-analysis. A handbook of bio-analysis and drug metabolism, Florida, CRC Press LLC; 2000: 4.1-4.8.

30. Veerendra K. Nanjwade, FV Manvi, Shamrez Ali. M, Basavaraj K. Nanjwade, Development and evaluation of Ivacaftor tablet. Int. journal of drug formulations and research. 2011; 2(6): 302-314.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com